CANF (Can Fite Biofarma) Accounts Payable & Accrued Expense : $1.32 Mil (As of Jun. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Can Fite Biofarma Accounts Payable & Accrued Expense?

Can Fite Biofarma's quarterly accounts payable & accrued expense declined from Sep. 2023 ($1.39 Mil) to Dec. 2023 ($0.68 Mil) but then increased from Dec. 2023 ($0.68 Mil) to Jun. 2024 ($1.32 Mil).

Can Fite Biofarma's annual accounts payable & accrued expense declined from Dec. 2021 ($1.26 Mil) to Dec. 2022 ($1.18 Mil) and declined from Dec. 2022 ($1.18 Mil) to Dec. 2023 ($0.68 Mil).

Can Fite Biofarma Accounts Payable & Accrued Expense Historical Data

The historical data trend for Can Fite Biofarma's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma Accounts Payable & Accrued Expense Chart

Can Fite Biofarma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

2.60

0.80

1.26

1.18

0.68

Can Fite Biofarma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															2.07	1.41	1.39	0.68	1.32

Can Fite Biofarma Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Can Fite Biofarma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (AMEX:CANF) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

CANF:Israel

Address

26 Ben Gurion Street, Ramat Gan, ISR, 5257346

Website

http://www.canfite.com

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).